Clinical DevelopmentThe upcoming update on the Phase 1 ascent-2 trial for PRX012 could provide visibility into the timing and content of update results, which might support a potential best-in-class product profile.
Financial PerformanceThe company ended the quarter with $565MM in cash and expects to end 2024 with ~$470MM, providing a strong foundation to execute on the development portfolio.
Pipeline ProgressContinued progress across the development pipeline with important clinical updates anticipated in 2H24.